Physician profile
Sharon T Wolf
NPI 1518942614
$1,220.59
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $136 · 2021: $23.63 · 2022: $14.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $447.34 | 2019-2020 | |
| Amgen INC. | $370.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $136.17 | 2019-2020 | |
| Astellas Pharma US INC | $58.25 | 2019-2021 | |
| Abbvie INC. | $51.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.87 | 2019 | |
| Novo Nordisk INC | $23.66 | 2019 | |
| Amarin Pharma, INC. | $23.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $14.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.10 | 2019 | |
| Pfizer INC. | $11.97 | 2019 | |
| Merck Sharp & Dohme LLC | $11.85 | 2019 | |
| Eisai INC. | $11.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.